汇宇制药(688553.SH):HY-2003临床试验申请获批

智通财经
26 Nov 2024

智通财经APP讯,汇宇制药(688553.SH)发布公告,公司收到国家药品监督管理局核准签发的《药物临床试验批准通知书》,公司自主研发的HY-2003的临床试验申请获得批准。

据悉,去氧胆酸通过物理方式破坏脂肪细胞并引发炎症反应,从而促使巨噬细胞清除受损脂肪细胞,达到溶解局部脂肪的效果。HY-2003为含有去氧胆酸的新剂型,以期降低注射部位不良反应、缩短用药间隔、加快起效时间、减少给药周期,拟用于改善成人颏下脂肪堆积造成的中至重度轮廓凸出。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10